Jun 08, 2020
Prime Therapeutics and EMD Serono ink value-based agreement on MAVENCLAD® (cladribine) tablets
Jun 02, 2020
icometrix launches its icompanion platform for people with multiple sclerosis
May 27, 2020
Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information to Help Inform Treatment Decisions for Women with MS
May 27, 2020
Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)
May 23, 2020
New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and Safety in MS Over 108 Weeks
May 05, 2020
Journal of Neuroinflammation Article Shows ZyVersa's Inflammasome Inhibitor, IC 100, Improves Functional Outcomes in an Animal Model of Multiple Sclerosis
Apr 30, 2020
Switching Patterns Among Relapsing-Remitting Multiple Sclerosis: Genentech's Ocrevus on the Rise, Biogen's Tecfidera Declines, and Teva's Copaxone Remains Strong, According to Spherix Global Insights
Apr 21, 2020
Harbour BioMed Announces First Patient Dosing of Phase 1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder
Apr 21, 2020
Multiple Sclerosis Drugs Industry Assessment 2020: Immunomodulators, Immunosuppressants, Interferons and Others
Apr 09, 2020
Roche's Ocrevus Continues to Impress in the EU with Strong Uptake in New Start and Switch Multiple Sclerosis Patient Segments, but Novartis' Mayzent and Ofatumumab May Threaten the Brand's Long-Term Dominance
Mar 19, 2020
Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast (2019 to 2027)
Mar 18, 2020
Janssen Submits Ponesimod New Drug Application to the U.S. FDA for Treatment of Adults with Relapsing Multiple Sclerosis
Mar 10, 2020
2020 Disease Analysis: Multiple Sclerosis - Sanofi to Co-Develop Digital Therapeutic for MS Patients
Mar 10, 2020
Genentech's Ocrevus Offers Stiff Competition to the New High-Efficacy Oral Therapies, Novartis' Mayzent and EMD Serono's Mavenclad, While Biogen's Vumerity Begins to Chip Away at the Company's Own Tecfidera
Mar 03, 2020
Novartis receives Health Canada approval for Mayzent(TM) (siponimod) to treat secondary progressive multiple sclerosis with active disease
Mar 02, 2020
Learn about the Mind, Body, and MS Connection During MSAA's 2020 MS Awareness Month Campaign
Mar 02, 2020
Learn about the Mind, Body, and MS Connection During MSAA's 2020 MS Awareness Month Campaign
Feb 27, 2020
Mallinckrodt to Present New Data from two Studies on Acthar® Gel (Repository Corticotropin Injection) Therapy in Multiple Sclerosis (MS) Relapse at Fifth Annual ACTRIMS Forum 2020
Feb 27, 2020
Clene Nanomedicine Presents Blinded Interim Data from the VISIONARY-MS Phase 2 Study
Feb 13, 2020
Consistent Efforts to Find Effective Drugs is Driving Growth of Multiple Sclerosis Drugs Market to Valuation of ~US$ 32 bn by 2027, Finds TMR